Fraser, G.
Cramer, P.
Demirkan, F.
Silva, R. Santucci
Grosicki, S.
Pristupa, A.
Janssens, A.
Mayer, J.
Bartlett, N. L.
Dilhuydy, M.-S.
Pylypenko, H.
Loscertales, J.
Avigdor, A.
Rule, S. http://orcid.org/0000-0001-8937-6351
Villa, D.
Samoilova, O.
Panagiotidis, P.
Goy, A.
Pavlovsky, M. A.
Karlsson, C.
Hallek, M.
Mahler, M.
Salman, M.
Sun, S.
Phelps, C.
Balasubramanian, S.
Howes, A.
Chanan-Khan, A.
Funding for this research was provided by:
This study was funded by Janssen Research & Development
Article History
Received: 12 February 2018
Revised: 9 May 2018
Accepted: 28 August 2018
First Online: 12 October 2018
Compliance with ethical standards
:
: GF: research support/honoraria: Janssen, Hoffmann-La Roche, Celgene; honoraria: Lundbeck, Abbvie. PC: research grants/honoraria/travel support: F. Hoffmann-La Roche, Janssen-Cilag; research grant/travel support: Gilead; research grant/honoraria: AstraZeneca, Novartis; research support/honoraria: AbbVie; travel support: Astellas, Mundipharma. FD: advisory board honorarium: Amgen; non-financial travel support: Janssen. RSS: research support: Roche Pharmaceuticals, GlaxoSmithKline, Celgene, Merck; personal fees: Novartis. AJ: educational grant: Janssen; travel support: Mundipharma, Abbvie; speakers’ fees: Janssen, Takeda, Roche, Abbvie; consulting fees: Janssen, Roche, Gilead, Abbvie. JM: grants: Janssen, Roche. NLB: advisory board fees: Gilead, Seattle Genetics. M-SD: fees: Janssen, Roche. JL: speakers’ bureaus/advisory boards: Janssen, Gilead, Roche. AA: grant: Janssen. SR: fees: Janssen, Pharmacyclics. DV: honoraria: Janssen, Lundbeck, Celgene, Genentech; research funding: Roche. PP: honoraria: Janssen. AG: speakers’ bureau/advisory board fees: Johnson & Johnson/Pharmacyclics, Takeda; consultancy/advisory board fees: Celgene. MAP: speaking/consulting honoraria: Novartis, Janssen. MH: honoraria/travel funds: Janssen; research funding/speakers’ bureau/advisory role: Roche; advisory role: Gilead Sciences. MM, MS, SS, CP, SB, AH: employees of Janssen. AC-K: institutional funding for this clinical trial. The other authors declare no competing interests.